Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog

Apr 29 2024

• By Derrick Gingery

backlog — CBER stopped deprioritizing non-COVID-19 submissions in 2023. • Source: Shutterstock

Related Content

Requests For In-Person Formal Meetings With US FDA Increasing, But Will They Ever Dominate Again?

Dec 21 2023

Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency

Feb 02 2023

US FDA’s Bioresearch Monitoring Program Should Evaluate Hiring And Retention Strategies, GAO Says

Apr 05 2024

The Wait Is Over: US FDA Advisory Committees Returning To In-Person Meetings Come Fall

Feb 26 2024

US FDA Implementing Hybrid Work Policy In January

Nov 22 2022

Complete Response Letters In Lieu Of Inspections: What To Expect During COVID-19

Aug 20 2020

CBER’s ‘Courageous’ Coronavirus Guidance Strategy May Catch-On

Jun 26 2020

US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

Jun 01 2020

Podcast: CDER’s Woodcock On COVID-19 – Missed User Fees Unlikely, But Some Work Will Be ‘Set Aside’

Apr 01 2020

US FDA Wants Global COVID-19 Vaccine Update System, But Says May Not Be Possible

Jan 24 2023

US FDA Biologics Group Emerging From Pandemic Footing – But Not Vaccines

Oct 28 2022

Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says

Feb 20 2021

Additional Topics

United States Vaccines Review Pathway Regulation Coronavirus COVID-19 BioPharmaceutical Infectious Diseases

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window